21
Feb
Feb
Probe: Diabetes drug maker kept risks quiet
Probe: Diabetes drug builder kept risks quiet
New York, N.Y. — A Senate inform pronounced Saturday which drug builder Glaxo-SmithKline knew of probable heart conflict risks scored equally to Avandia, the diabetes drug, years prior to such justification became public.
Read some-more upon The Des Moines Register